arGEN-X, a biopharmaceutical company based in The Netherlands and focused on human monoclonal antibodies from its proprietary SIMPLE Antibody platform, has strengthened its supervisory board with the appointment of Dr. David L. Lacey.

Lacey has over 30 years of basic and clinical research experience and formerly served as senior vice president and dead of discovery research at Amgen. He played a fundamental role in the discovery of the OPG/RANKL/RANK pathway at Amgen, as well as the development of the human anti-RANKL mAb denosumab, which was approved in 2010 by the FDA under the trade name Prolia, to treat osteoporosis in postmenopausal women, and as Xgeva, for the prevention of skeletal-related events in metastatic bone tumors.